Yarrow Bioscience (NASDAQ:YARW) Short Interest Update

Yarrow Bioscience (NASDAQ:YARW) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 12,582 shares, a drop of 93.2% from the July 15th total of 183,974 shares. Based on an average daily trading volume, of 38,657 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.9% of the company’s shares are short sold.

Analyst Ratings Changes

YARW has been the topic of several research analyst reports. BTIG Research started coverage on Yarrow Bioscience in a research note on Monday, August 3rd. They set a “buy” rating and a $58.00 target price on the stock. TD Cowen assumed coverage on shares of Yarrow Bioscience in a report on Tuesday, July 28th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $58.00.

Yarrow Bioscience Price Performance

Shares of NASDAQ YARW traded up $0.97 during midday trading on Tuesday, hitting $42.94. 5,423 shares of the company traded hands, compared to its average volume of 11,468. Yarrow Bioscience has a 12-month low of $14.02 and a 12-month high of $46.95. The stock has a market capitalization of $28.77 million, a P/E ratio of -2.26 and a beta of 1.95.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.